Immediate action of L-2,3,5,6-tetrahydrophenylimido (2,1b) azothiazol (Levamisole) on the phagocytosis of inert radiocolloidal particles.
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
A F Rojas
Publications and source records attributed to A F Rojas.
Adjuvant treatment with levamisole in cancer: a review of experimental and clinical data.
Animal and human studies of adjuvant treatment with levamisole in cancer are reviewed and discussed. From the animal data it is concluded that the activity of levamisole is dose-dependent, more effective on slow-growing tumors, affects metastasis formation, preferentially is best when levamisole is used as an adjuvant to the usual cytoreductive treatments and that tumor enhancement is not expected. Clinical findings are put into perspective of the animal data and the most appropriate clinical situations are indicated.
Animals↗
Levamisole in advanced human breast cancer.
A clinical trial of levamisole, an orally effective modifier of the immune response, is reported in women with primary inoperable breast cancer (stage III). After being rendered clinically disease-free by radiotherapy to the breast, supraclavicular area, and axilla, patients were allocated alternately to a control group (no further treatment) and a levamisole-treated group (150 mg orally three times a week on alternate weeks) and were followed-up by physical examination and laboratory tests. In 43 patients (23 control and 20 levamisole), there was significant prolongation of the median disease-free interval (25 v. 9 months) and survival (90% v. 35% alive at 30 months) in the levamisole-treated group compared with the controls. Levamisole treatment was also associated with an increase in the percentage and intensity of delayed hypersensitivity skin reactions and in the absolute lymphocyte-counts. No significant toxicity of levamisole was observed.
Administration, Oral↗